Cerevance's solengepras (CVN424) has entered a Phase 3 trial (ARISE) as an adjunctive therapy for Parkinson's disease, with topline data expected in the first half of 2026.
Sage Therapeutics discontinues dalzanemdor (SAGE-718) development after its Phase II DIMENSION trial failed to meet primary and secondary endpoints in Huntington's disease patients.
Sage Therapeutics discontinues dalzanemdor (SAGE-718) development after its Phase II DIMENSION trial failed to meet primary and secondary endpoints in Huntington's disease patients.
Sage Therapeutics has discontinued its Huntington's disease program after its investigational therapy, SAGE-718, failed to meet primary endpoints in a Phase II clinical trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.